Analysis of the availability of drugs for nebulizer therapy on the pharmaceutical market of Ukraine

Read full text Summarise with VIRAT
Authors: М. В. Савохина, О. В. Ткачова
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective. To conduct a comprehensive analysis of the assortment, systematization of medicinal products for nebulizer therapy on the pharmaceutical market of Ukraine in 2025 by INN, ATC classification, manufacturers, and indications for use, with the aim of rationalizing the pharmaceutical supply of nebulizer therapy. Methods. Official electronic resources were used for the analysis of the pharmaceutical market of drugs for nebulizer therapy: the State Register of Medicinal Products of Ukraine, Compendium Online, and the Tabletki.ua portal. Drugs were systematized by INN, dosage form, pharmacotherapeutic group, and ATC classification. Results. The assortment of drugs for nebulizer therapy in Ukraine is diverse and covers the main areas of pharmacotherapy: BA (Salbutamol, Fenoterol, Budesonide); COPD (Ipratropium bromide, Tiotropium bromide); acute and obstructive bronchitis, tracheitis (Ambroxol, Acetylcysteine); cystic fibrosis, chronic purulent bronchitis (Tobramycin, Thiamfenicol, Dornase alfa, Colistin, and others); ARI, rhinopharyngitis, laryngitis, and sinusitis (Decamethoxin, Sodium chloride, Ectoine, Hyaluronic acid), postoperative respiratory rehabilitation (Ambroxol, Decamethoxin, and others), allergic rhinitis and bronchial hyperreactivity (Ectoine, seawater, Sodium chloride), primary pulmonary hypertension NYHA III (Iloprost), and antiseptics/antibiotics. Domestic manufacturers (Yuriya-Pharm, Farmak, Zdorovya, Farmasel) hold leading positions in terms of the number of trade names, which contributes to local production and drug availability. In terms of the number of registered MPs for nebulizer therapy, mucolytics based on Ambroxol (7 trade names, 17.95%) and the category of medical devices (8 trade names, 20.51%) based on hyaluronic acid, seawater, ectoine, and sodium chloride are leading. Conclusions. The market corresponds to modern approaches to the treatment of chronic respiratory diseases and has a high level of therapeutic coverage. However, the nebulizer drug market in Ukraine is relatively limited, listing about 30 trade names and 8 medical devices, while in EU countries, the number of nebulizer drugs exceeds 60–70 positions, including the latest forms of antibiotics and combination agents.

Fields of Study & Subjects

Pharmaceutical Economics and Policy Medical and Pharmaceutic Studies Inhalation and Respiratory Drug Delivery

Publication details

Journal / source
Likarska sprava
Issue
1
Pages
123–130
Publication date
31 March 2026
Language
EN